v3.22.2.2
Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Fair Value Disclosures [Abstract]        
Net (gains)/losses recognized during the period on equity securities [1],[2] $ 112 $ (400) $ 1,353 $ (1,601)
Less: Net (gains)/losses recognized during the period on equity securities sold during the period (5) (78) (84) (83)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date [3] $ 116 $ (322) $ 1,436 $ (1,518)
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The losses in the first nine months of 2022 include, among other things, unrealized losses of $974 million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420 million and $1.5 billion, respectively, related to investments in BioNTech and Cerevel.
[3] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October 2, 2022, there were cumulative impairments and downward adjustments of $148 million and upward adjustments of $201 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.